M&A May Be the Legacy of the Trump Tax Cuts for Pharma

글 내용 전체보기

Allergan CEO Says Underlying Core Business Is Growing, Pipeline Is Encouraging

글 내용 전체보기

Takeda Plans to Sell $10 Billion in Non-Core Assets to Offset Debt of the Shire Deal

글 내용 전체보기

Your Feedback Matters! Topics in 2019

글 내용 전체보기

Moderna Stock Pops 4.2% on Clinical Update

글 내용 전체보기

Where Are They Now? Top 3 Biotech Startups From NextGen Bio Class of 2015

글 내용 전체보기

JP Morgan Healthcare Conference Update: FDA, bluebird, Moderna and the Price of Coffee

글 내용 전체보기

Eli Lilly CEO Expresses Confidence for the Company in the New Year

글 내용 전체보기

With Likely Approvals on the Way, Bluebird Bio Offers up Pricing Strategy for Gene Therapy

글 내용 전체보기

Don’t fret about Lilly’s 3rd-to-market start in CGRP, executive says. It’s got big plans in migraine and pain

글 내용 전체보기

With pivot to less-rare diseases, Alexion needs a new sticker-price plan, CEO says

글 내용 전체보기

With Tesaro in the bag, GSK’s cancer pipeline is pumping again, CEO says

글 내용 전체보기

Eli Lilly’s new Trulicity TV ad counters Trump with first-ever pricing information

글 내용 전체보기

Regeneron’s Eylea hits double-digit growth for 2018, and it’s ‘far from done,’ CEO says

글 내용 전체보기

Trump, frustrated over latest hikes, calls White House meeting on prices: report

글 내용 전체보기

Pfizer puts 1,700 jobs in jeopardy with 2 Hospira plant shutdowns in India

글 내용 전체보기

Amgen’s Repatha hits wall at SCOTUS but presses ahead—new price breaks included

글 내용 전체보기

J&J still sees plenty of opportunity in crowded immunology markets—starting with psoriasis

글 내용 전체보기

With new data, new targets, Tmunity Therapeutics to gather steam in 2019

글 내용 전체보기

Basilea posts interim pivotal data on ArQule-partnered cancer drug

글 내용 전체보기

Amgen gets first OK for Evenity in Japan as FDA panel looms

글 내용 전체보기